Europe
4basebio AG announces the allotment ratio and the final number of shares for the announced share buyback program.
Polyphor AG, a research based clinical stage biopharmaceutical company, announces progress of the Phase III immuno-oncology program with balixafortide and a renewed strategy in advancing antibiotics and oncology research and pipeline.
Seqirus snagged approval for Fluad Quadrivalent, the first-and-only quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
H. Lundbeck A/S is making a statement with its newly approved treatment for migraine, the first intravenous medication approved for the preventative treatment of migraine.
The brands Stada is picking up include venous treatment Venoruton, Coldrex for colds, Cetebe vitamin C supplements, Mebucaine for sore threats and Tavegyl for allergies, among others.
The U.S. Food and Drug Administration is compiling a list of drugs that are at risk of shortage if the outbreak in China continues to worsen.
Mid-February had a solid number of clinical trial announcements. Here’s a look.
Agreement gives BIA Separations access to proprietary technology to better preserve integrity, infectivity and potency of immunoaffinity-purified viral vectors for gene therapy
Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology
Montis Biosciences announces its launch with €8,4 million in seed financing from an international investor syndicate to investigate interactions between perivascular macrophages and tumor vasculature.
PRESS RELEASES